Why Insurance Doesn’t Cover PRP Injections (And What the Evidence Shows)
Updated: Aug 24
By Dr. Jeffrey Peng, MD · Updated August 2026
Watch the Full Video
One of the most common questions patients ask at their first consultation is whether their health insurance will cover platelet-rich plasma (PRP) injections. It is an understandable concern — PRP is one of the most effective nonsurgical treatments available for conditions like knee osteoarthritis and chronic tendon injuries, yet the vast majority of insurance companies in the United States still refuse to cover it.
This article explains why that gap exists, what the evidence actually shows, and what it will take for coverage to change.
Which Insurance Plans Currently Cover PRP?
As of this writing, the only health insurance plan in the United States that covers PRP injections is Tricare, the healthcare program for active-duty military service members and their families. This makes intuitive sense — the military has a direct financial incentive to return service members to full physical readiness as quickly and effectively as possible.
Every other major insurer — including Cigna, Blue Cross Blue Shield, Aetna, UnitedHealthcare, and Medicare — still classifies PRP as experimental or investigational and declines coverage. In my practice, this is one of the most frustrating barriers patients face when pursuing evidence-based nonsurgical care.
What Does the Research Say About PRP Effectiveness?
Despite what insurance companies claim, there is now substantial evidence supporting PRP as a safe and effective treatment for multiple musculoskeletal conditions. Consider knee osteoarthritis alone: multiple randomized controlled trials, systematic reviews, and meta-analyses have demonstrated that PRP injections produce better patient outcomes than corticosteroids, hyaluronic acid, and placebo for the treatment of mild to moderate symptomatic knee osteoarthritis. Newer studies have even suggested that PRP may slow the structural progression of arthritis and delay the need for joint replacement surgery.
The benefits extend beyond the knee. PRP has also been shown to be superior to other nonsurgical treatments for common conditions such as tennis elbow and golfer’s elbow. A systematic review published in Arthroscopy found that PRP injections offered similar levels of improvement in pain and function when compared to surgery for lateral epicondylitis (Hardy et al., 2021).
What Do Major Medical Societies Say About PRP?
It is not just individual clinical trials that support PRP — major medical organizations have weighed in as well.
European Alliance of Associations for Rheumatology (EULAR)
A task force presented at the 2020 EULAR E-Congress developed a consensus statement concluding that intra-articular PRP injections are an effective symptomatic treatment for early to moderate knee osteoarthritis, that PRP may also be useful in severe knee osteoarthritis, and that PRP treatment should be offered as a second-line option after failure of oral or nonpharmacological treatments.
American Academy of Orthopaedic Surgeons (AAOS)
The AAOS published a technology overview on PRP for knee osteoarthritis. The authors concluded that the literature supports the hypothesis that PRP can offer statistically significant benefit compared to placebo and active treatment alternatives such as hyaluronic acid, corticosteroids, and NSAIDs for patient-reported outcomes related to pain and symptoms at time points up to 12 months.
American Medical Society for Sports Medicine (AMSSM)
The AMSSM released a position statement on the responsible use of regenerative medicine and orthobiologics. The statement noted that research suggests PRP injections are more effective in reducing pain and improving function than steroid or hyaluronic acid injections for knee osteoarthritis, particularly in patients who are younger and have mild to moderate disease. For tendons, the statement highlighted positive randomized controlled trial results for lateral epicondylitis, gluteus medius tendinopathy, and plantar fasciopathy.
Why Do Insurance Companies Still Refuse to Cover PRP?
Two main arguments are commonly used.
The safety argument is not credible. PRP is derived entirely from the patient’s own blood — it is autologous — making it one of the safest injectable treatments available. Multiple randomized controlled trials and systematic reviews have confirmed a favorable long-term safety profile. Interestingly, the same cannot be said of cortisone injections, which are universally covered by insurance despite evidence that repeated steroid injections can weaken tendons and damage healthy cartilage.
A more nuanced objection is that some clinical trials have found PRP to be no better than placebo. Insurers point to trials such as the RESTORE trial and the PEAK trial as evidence that PRP does not work for knee osteoarthritis. However, this interpretation misses a critical nuance: not all PRP is the same, and dosing matters enormously.
Does PRP Dosing Affect Clinical Outcomes?
Just as with any pharmaceutical intervention, the dose of PRP matters. The RESTORE trial used a preparation kit that produced approximately 1 to 2 billion platelets. The PEAK trial used a kit that yielded approximately 2 to 3 billion platelets. Emerging clinical data now demonstrate a clear dose-response curve for PRP, and the threshold for clinical benefit in knee osteoarthritis appears to be approximately 10 billion platelets, which typically requires a blood draw of at least 60 cc.
What the RESTORE and PEAK trials actually demonstrated is that low-dose PRP is not effective for knee osteoarthritis — a finding that is entirely consistent with dose-response pharmacology. This is why newer studies are investigating the higher end of the dose-response curve, starting with blood draws of 60 cc and extending up to 120 cc.
PRP Dosing Guide: How Blood Draw Volume Affects Platelet Count
• 10 cc blood draw → ~1.5–2.4 billion platelets (low dose, similar to RESTORE trial)
• 20 cc → ~3.0–4.8 billion platelets (low dose, similar to PEAK trial)
• 30 cc → ~4.5–7.2 billion platelets (moderate dose, suitable for smaller joints)
• 60 cc → ~9.0–14.4 billion platelets (therapeutic dose for large joints — recommended target)
• 80–120 cc → higher doses used in newer research protocols
For large joints such as knees, hips, and shoulders, aim for a 60 cc blood draw yielding approximately 10 billion platelets. Smaller joints may respond to a 30 cc draw.
Will Cost-Benefit Data Finally Change Insurance Coverage?
In my opinion, the factor most likely to shift insurance coverage is not more efficacy data — it is economic data demonstrating that PRP saves money in the long run. One notable cost-utility analysis found that PRP, compared to other injections, was the most cost-effective treatment option for patients with mild and moderate knee osteoarthritis.
Patients who receive effective PRP treatment experience better symptom control and improved function, which enables them to remain physically active, maintain employment productivity, and exercise regularly. The downstream effects — reduced rates of obesity, diabetes, hypertension, and other comorbidities — translate into substantial long-term healthcare savings.
How Can Patients Ensure They Are Getting High Quality PRP?
If you are considering PRP and will be paying out of pocket, it is essential to ensure you are receiving a high-quality, appropriately dosed treatment. Ask your provider about the volume of blood drawn, the preparation system used, and the approximate platelet count of the final product. For large joints such as the knee, hip, or shoulder, a blood draw of at least 60 cc — yielding approximately 10 billion platelets — is the current target based on emerging evidence.
If you are interested in learning more about PRP therapy or schedule a consultation to discuss whether PRP is appropriate for your condition.
References
1. Hardy R, et al. To Improve Pain and Function, Platelet-Rich Plasma Injections May Be an Alternative to Surgery for Treating Lateral Epicondylitis: A Systematic Review. Arthroscopy. 2021;37(11):3360-3367. doi:10.1016/j.arthro.2021.04.043
2. Bennell KL, et al. Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial. JAMA. 2021;326(20):2021-2030. doi:10.1001/jama.2021.19415
3. The effectiveness of leucocyte-poor platelet-rich plasma injections on symptomatic early osteoarthritis of the knee: The PEAK randomized controlled trial. Bone Joint J. 2022;104-B(6):663-671. PMID: 35638203
4. Finnoff JT, et al. American Medical Society for Sports Medicine Position Statement: Principles for the Responsible Use of Regenerative Medicine in Sports Medicine. Clin J Sport Med. 2021;31(6):530-541. doi:10.1097/JSM.0000000000000973
5. Raeissadat SA, et al. Cost-utility analysis and net monetary benefit of Platelet Rich Plasma (PRP) intra-articular injections... BMC Musculoskelet Disord. 2023;24(1):22. doi:10.1186/s12891-022-06114-x
6. Eymard F. Consensus Statement on Intra-Articular Injections of Platelet-Rich Plasma for the Management of Knee Osteoarthritis. Abstract AB0862. 2020 EULAR E-Congress.
7. American Academy of Orthopaedic Surgeons. Technology Overview: Platelet-Rich Plasma for Knee Osteoarthritis. AAOS.org
Medical Disclaimer: This content is for educational purposes only and does not substitute for the medical advice of a physician. Always consult your healthcare provider before beginning any new treatment program. The information presented reflects the opinion of Dr. Jeffrey Peng and does not represent the views of his employers or affiliated hospital systems.
Comments